# Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B

> **NCT02695160** · PHASE1 · TERMINATED · sponsor: **Sangamo Therapeutics** · enrollment: 1 (actual)

## Conditions studied

- Hemophilia B

## Interventions

- **BIOLOGICAL:** SB-FIX

## Key facts

- **NCT ID:** NCT02695160
- **Lead sponsor:** Sangamo Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11-15
- **Primary completion:** 2021-04-19
- **Final completion:** 2021-04-19
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2024-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02695160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02695160, "Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02695160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*